Processing

Please wait...

Settings

Settings

1. WO2015110826 - (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS

Publication Number WO/2015/110826
Publication Date 30.07.2015
International Application No. PCT/GB2015/050155
International Filing Date 23.01.2015
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
267
Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
02
Seven-membered rings
08
having the hetero atoms in positions 1 and 4
10
not condensed with other rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
553
having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
C07D 267/10 (2006.01)
C07D 413/14 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)
A61K 31/553 (2006.01)
A61P 11/00 (2006.01)
CPC
A61K 31/553
A61K 45/06
C07D 267/10
C07D 413/12
C07D 413/14
C07D 417/12
Applicants
  • ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje, SE (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW)
  • ASTRAZENECA UK LIMITED [GB/GB]; 2 Kingdom Street London Greater London W2 6BD, GB (MG)
Inventors
  • LÖNN, Hans, Roland; GB
  • CONNOLLY, Stephen; GB
  • SWALLOW, Steven; GB
  • KARLSSON, Staffan PO; SE
  • AURELL, Carl-Johan; SE
  • PONTÉN, John Fritiof; GB
  • DOYLE, Kevin, James; GB
  • VAN DE POËL, Amanda, Jane; GB
  • JONES, Graham, Peter; GB
  • WATSON, David, Wyn; GB
  • MACRITCHIE, Jaqueline, Anne; GB
  • PALMER, Nicholas, John; GB
Agents
  • ASTRAZENECA INTELLECTUAL PROPERTY; AstraZeneca Mereside Alderley Park Macclesfield Cheshire SK10 4TG, GB
Priority Data
61/931,09024.01.2014US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS
(FR) (2S)-N-[(1S)-1-CYANO-2-PHÉNYLÉTHYL]-1,4-OXAZÉPANE-2-CARBOXAMIDES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE I
Abstract
(EN)
The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), (Formula (I)) that inhibit dipeptidyl peptidase 1(DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
(FR)
La présente invention concerne certains composés de (2S)-N-[(1S)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamide (comprenant des sels pharmaceutiquement acceptables correspondants) (formule (I)) qui inhibent l'activité de la dipeptidyl peptidase 1 (DPP1), leur utilité dans le traitement et/ou la prévention d'affections cliniques comprenant les maladies respiratoires, telles que l'asthme et la bronchopneumopathie chronique obstructive (BPCO), leur utilisation en thérapie, des compositions pharmaceutiques les contenant et des procédés pour préparer ces composés.
Latest bibliographic data on file with the International Bureau